CN1823802A - Gastrodin slow release preparation - Google Patents
Gastrodin slow release preparation Download PDFInfo
- Publication number
- CN1823802A CN1823802A CN 200510048255 CN200510048255A CN1823802A CN 1823802 A CN1823802 A CN 1823802A CN 200510048255 CN200510048255 CN 200510048255 CN 200510048255 A CN200510048255 A CN 200510048255A CN 1823802 A CN1823802 A CN 1823802A
- Authority
- CN
- China
- Prior art keywords
- preparation
- gastrodine
- cellulose
- release
- slow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
A slow-releasing gastrodine and its preparing process are disclosed.
Description
Technical field
The present invention relates to pharmaceutical preparation and preparation method thereof, more specifically, the invention discloses a kind of gastrodin slow release preparation and preparation method thereof.
Background technology
Because the quickening of work, rhythm of life, the patient of neurasthenia, neurasthenia syndrome, angioneurotic headache etc. is more and more, reached 13%, and such disease there is no specific Therapeutic Method and medicine at present, bring misery for patient's work, life, have multiplely though be used for the medicine of neurasthenia, neurasthenia syndrome, angioneurotic headache, still do not have specific medicine.Therefore, can improve the little medicine of symptom, toxic and side effects just extensively welcome by the patient.
The gastrodine chemical name is 4-hydroxy benzenes-β-D pyranglucoside, is spiritual neurological drug.It has water solublity, resolves into gastrodin unit in vivo.Gastrodin unit is fat-soluble, easily sees through blood brain barrier in vivo under the condition, combines with benzodiazepine receptors on the cell membrane then, strengthens the affinity of gamma-aminobutyric acid receptor, and then performance maincenter depression effect.Gastrodine is used for diseases such as neurasthenia, neurasthenia syndrome and angioneurotic headache (as migraine, trigeminal neuralgia, occipital bone neuralgia etc.) clinically.Gastrodine has curative effect preferably, and is nontoxic, and untoward reaction is slight, is the better medicine of treatment neurasthenia, neurasthenia syndrome, angioneurotic headache, for dizzy, tinnitus etc. therapeutical effect preferably arranged also.In the spiritual class medicine of nerve, the sales volume of gastrodine occupies top ten always, and its welcome degree also is described.
The gastrodine preparation that has gone on the market at present is a common oral preparation, and common oral preparation is taken often, the blood drug level instability, and compliance is poor, and its indication medicining cycle is long.Therefore develop blood drug stabilisation, compliance preferably the gastrodine oral formulations be the problem that those skilled in the art puts forth effort to solve always.
Summary of the invention
The invention discloses:
1. a gastrodin slow release preparation contains gastrodine and pharmaceutically useful slow-release auxiliary material.
2. above-mentioned 1 preparation, wherein pharmaceutically useful slow-release auxiliary material is a hydroxypropyl emthylcellulose, hydroxypropylmethyl cellulose phthalate, methylcellulose, ethyl cellulose, hydroxy methocel, hydroxyethyl-cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, acrylic resin, polymethyl methacrylate, crospolyvinylpyrrolidone, sodium alginate, calcium alginate, carbomer, polyvinyl alcohol, stearic acid, a kind of or its mixture in the chitosan, preferred hydroxypropyl methylcellulose HMPC, the more preferably mixture of HPMC-75RT15000 and HPMC-75RT4000.
3. above-mentioned 1 or 2 preparation also contains excipient, and excipient is one of microcrystalline Cellulose, lactose, sucrose, mannitol, dextran, sorbitol, starch, pregelatinized Starch, dextrin, calcium sulfate, calcium hydrogen phosphate or its mixture.
4. above-mentioned 3 preparation, wherein gastrodine/pharmaceutically useful slow-release auxiliary material/excipient is 1: 0.5～3.0: 0.5～2.0 by weight.
5. above-mentioned arbitrary preparation, also contain binding agent, lubricant, binding agent is a kind of or its mixture in polyvinylpyrrolidone, starch slurry, syrup, water, the ethanol, and lubricant is a kind of or its mixture in stearic acid, magnesium stearate, calcium stearate, Pulvis Talci, silicon dioxide, micropowder silica gel, Polyethylene Glycol, Stepanol MG, the sodium lauryl sulphate.
6. above-mentioned 5 preparation, wherein gastrodine/lubricant is 1: 0.02～0.5 by weight.
7. above-mentioned 5 preparation, wherein volume ratio or weight ratio are 1: 0.001～0.005 to gastrodine/binding agent by weight.
8. the arbitrary preparation of above-mentioned 6-7, wherein each components contents of unit formulation is:
Gastrodine 75mg
HPMC-75RT15000 54mg
HPMC-75RT4000 54mg
Microcrystalline Cellulose 84.3mg
The 75% alcoholic solution 0.2ml of 3%PVP
Magnesium stearate 2.7mg
9. above-mentioned arbitrary preparation can be tablet, capsule, granule, pill and coated slow release preparation, preferred coated tablet.
10. above-mentioned 9 preparation, wherein coating powder is a GS-N type coating powder in the coated tablet, the coating weightening finish is 2～5% by weight percentage.
More specifically, the present inventor has carried out a large amount of experiments, excipient substance is screened, obtained a kind of gastrodin slow release preparation, contain gastrodine and pharmaceutically useful slow-release auxiliary material, wherein slow-release auxiliary material is a hydroxypropyl emthylcellulose, hydroxypropylmethyl cellulose phthalate, methylcellulose, ethyl cellulose, hydroxy methocel, hydroxyethyl-cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, acrylic resin, polymethyl methacrylate, crospolyvinylpyrrolidone, sodium alginate, calcium alginate, carbomer, polyvinyl alcohol, stearic acid, a kind of or its mixture in the chitosan, preferred hydroxypropyl methylcellulose HMPC, more preferably the mixture of HPMC-75RT15000 and HPMC-75RT4000 is the hydrogel matrix slow releasing preparation of cellulose derivative preparation.Preparation of the present invention also contains excipient (diluent), excipient (diluent) is a microcrystalline Cellulose, lactose, sucrose, mannitol, dextran, sorbitol, starch, pregelatinized Starch, dextrin, calcium sulfate, one of calcium hydrogen phosphate or its mixture, by weight each component gastrodine/pharmaceutically useful slow-release auxiliary material/excipient is 1: 0.5～3.0: 0.5～2.0, because gastrodine is a water soluble drug, the release of medicine is difficult for being brought under control, the present inventor is in order to reach ideal slow release effect, make the consumption of slow-release auxiliary material reach certain requirement, through a large amount of tests, utilize HPMC-75RT15000 and HPMC-75RT4000 as slow-release auxiliary material, when HPMC-75RT4000: HPMC-75RT15000 is 1: 1, make the release in vitro degree of gastrodin slow release sheet be: 1h is 20%～40%, 2h is 35%～60%, 4h is 50%～80%, 8h＞80%, and all substantially near the mid point of each release critical field, the total amount that has obtained two kinds of HPMC accounts for 40% of prescription, and ratio is can obtain the conclusion of best release profiles at 1: 1 o'clock.
Preparation of the present invention also contains binding agent, lubricant, wherein binding agent is a polyvinylpyrrolidone, starch slurry, syrup, water, a kind of or its mixture in the ethanol, 75% alcoholic solution of preferred 3%PVP, its consumption is that volume ratio or weight ratio are 1: 0.001～0.005 (g/l) to gastrodine/binding agent by weight, lubricant is a stearic acid, magnesium stearate, calcium stearate, Pulvis Talci, silicon dioxide, micropowder silica gel, Polyethylene Glycol, Stepanol MG, a kind of or its mixture in the sodium lauryl sulphate, preferred magnesium stearate, its consumption: gastrodine/lubricant is 1: 0.02～0.5 by weight.
Preparation of the present invention can be granule, pill etc., the solid sustained-release preparation that uses coating to make in addition., since the gastrodine bitter in the mouth, the preferred coated tablet of the present invention.We carry out film coating to the gastrodin slow release sheet, adopt the GS-N type coating powder of Shandong Rui Tai company, and being mixed with concentration according to its operation instructions is 8% coating solution, and the gastrodin slow release sheet is carried out coating.The total formulation weight amount/coating powder weight is 1: 0.02～0.05 before the coating.
The invention also discloses preparing such formulations, comprise that wet granulation, tabletting, coating are (for the ordinary tablet directly compressible, for coated tablet is film coating, for capsule direct fill capsule before the tabletting then) three steps of technology, wherein the wet granulation step is the supplementary material that takes by weighing recipe quantity, crosses 80 mesh sieves respectively; With gastrodine, slow-release auxiliary material, excipient mixing, add binding agent and make wetting agent system soft material, cross 20 mesh sieves and granulate; Wet granular is in 50-60 ℃ of oven dry, with 18 mesh sieve granulate.Tabletting is for to add the lubricant mixing in dried granule, detection level, tabletting.Art for coating is the preparation coating solution: take by weighing coating powder by prescription, by specification is prepared 8% coating solution.Get the label that is up to the standards, the bag film-coat, weightening finish is about 2～5%.Pack then finished product.
The preparation that the present invention obtains is through the experiment of release in vitro degree, with conventional tablet, each 50mg～100mg compares for 3 times on the one, can be 2 times on the one, be decided to be 75mg by specification, took once in 12 hours, take 1～2 at every turn, one day dosage and ordinary tablet are suitable, and dosage is adjusted easily, can satisfy patient's needs in various degree, has reached the effect of invention.
Description of drawings:
The numb plain slow releasing preparation release curve that accompanying drawing 1: embodiment 1 obtains.
The specific embodiment:
Following examples, test example only are used for illustrating the present invention, should not be construed as limitation of the present invention.
Coating powder: the GS-N type coating powder of Shandong Rui Tai company
The present invention unless stated otherwise, all raw material is commercially available.
The preparation of embodiment gastrodin slow release preparation
The preparation of embodiment 1 gastrodin slow release coated tablet
Prescription
The label prescription:
Composition weight
Gastrodine 75mg
HPMC-75RT15000 54mg
HPMC-75RT4000 54mg
Microcrystalline Cellulose 84.3mg
The 75% alcoholic solution 0.2ml of 3%PVP
Magnesium stearate 2.7mg
The coating prescription:
GS-N type coating powder 8.1mg
Preparation method:
Label technology:
(1) pulverizes: take by weighing the supplementary material of recipe quantity, cross 80 mesh sieves respectively;
(2) granulate: with gastrodine, hypromellose, microcrystalline Cellulose mixing, 75% alcoholic solution that adds 3%PVP is made wetting agent system soft material, crosses 20 mesh sieves and granulates.
(3) dry, granulate: wet granular is in 50-60 ℃ of oven dry, with 18 mesh sieve granulate.
(4) tabletting: in dried granule, add the magnesium stearate mixing, detection level, tabletting.
Art for coating:
(1) preparation coating solution: take by weighing coating powder by prescription, by specification is prepared 8% coating solution.
(2) coating: get the label that is up to the standards, the bag film-coat, weightening finish is about 3%.
Packing:
Get Film coated tablets, check, packing gets product.
The preparation of embodiment 2 gastrodin slow release sheets
Prescription: composition weight
Gastrodine 75mg
HPMC-75RT15000 54mg
HPMC-75RT4000 54mg
Microcrystalline Cellulose 84.3mg
The 75% alcoholic solution 0.16ml of 3%PVP
Magnesium stearate 2.7mg
Preparation method: behind gastrodine, hydroxypropyl emthylcellulose, microcrystalline Cellulose wet granulation, granulate, add the magnesium stearate mixing, the control tablet weight, tabletting promptly gets the gastrodin slow release sheet.
The preparation of embodiment 3 gastrodin slow release tablets/capsules
Prescription: composition weight
Gastrodine 75mg
Sodium alginate 66mg
Calcium alginate 10mg
Lactose 40mg
Magnesium stearate 2mg
Water (or ethanol water) 0.3ml
Preparation method: with gastrodine, sodium alginate, calcium alginate, the abundant mix homogeneously of lactose, add suitable quantity of water (or ethanol water) and make soft material, the back oven dry of granulating, granulate adds the magnesium stearate mixing, the control tablet weight, tabletting is promptly.Also can behind granulation, drying, granulate, granule be added in the Capsules, promptly make the gastrodin slow release capsule.
The preparation of embodiment 4 gastrodin slow release sheets
Prescription: composition weight
Gastrodine 75mg
Hydroxypropyl emthylcellulose (K
15M) 25mg
Ethyl cellulose 13mg
Sorbitol 60mg
Microcrystalline Cellulose 50mg
Pulvis Talci 4mg
10% polyvinylpyrrolidone aqueous solution is an amount of
Preparation method: with gastrodine, hydroxypropyl emthylcellulose, ethyl cellulose, sorbitol, microcrystalline Cellulose mix homogeneously, with polyvinylpyrrolidone wet granulation, oven dry, the adding Pulvis Talci is wet even behind the granulate, the control tablet weight, and tabletting is promptly.
The preparation of embodiment 5 gastrodin slow release coated tablet
Prescription: composition weight
Sheet core segment: gastrodine 75mg
Polyvinylpyrrolidone 4.5mg
Lactose 40.5mg
Water is an amount of
Lubricant 30mg
The coating part: acrylic resin is an amount of
10% polyvinylpyrrolidone alcoholic solution is an amount of
Preparation method: with gastrodine, polyvinylpyrrolidone, lactose mix homogeneously, water is made soft material with above-mentioned material, and wet granulation, oven dry add lubricant behind the granulate, the control tablet weight, and tabletting is made label.
Get acrylic resin and 10% polyvinylpyrrolidone alcoholic solution is an amount of, its dissolving as coating solution, is promptly got gastrodine coated slow release sheet to the label coating.
Acrylic resin is the undissolved clothing membrane material of gastrointestinal tract, adds an amount of polyvinylpyrrolidone as porogen in coating solution, dissolving in Digestive system and make and occur micropore on the clothing film, and medicine discharges from micropore, reaches the effect of slow release.
Test the release test of routine gastrodin slow release preparation
Test apparatus:
The intelligent medicament dissolution instrument of RCZ-8A, Precision Instrument Factory, Tianjin Univ.
The UV-1900 ultraviolet-uisible spectrophotometer, the Beijing Puxi General Instrument Co., Ltd
Test method:
According to 2000 editions two appendix XD of Chinese Pharmacopoeia (drug release determination method), first methods (being used for slow releasing preparation or controlled release preparation), adopt the device of dissolution method first method (basket method) to measure.We carry out release research for water.
Release conditions: medium: water (1000ml); Rotating speed: 100 rev/mins; Temperature: 37 ℃.
Press three batch samples of embodiment 1 preparation, respectively get 6, according to drug release determination method first method (two appendix XD of Chinese Pharmacopoeia version in 2000), with dissolution method first method (changeing the basket method) (two appendix XC of Chinese Pharmacopoeia version in 2000) device, with 1000ml water is solvent, Revolution Per Minute 100 changes, operation in accordance with the law, got solution 5ml (the instant water that in process container, replenishes with volume) respectively at 1 hour, 2 hours, 4 hours and 8 hours, through the 0.45um membrane filtration, discard filtrate just, precision measure subsequent filtrate 1ml with solvent dilution to 5ml as need testing solution; It is an amount of that precision takes by weighing the gastrodine reference substance in addition, and water is made the solution that contains 16ug among every 1ml approximately; Get above-mentioned two kinds of solution, according to spectrophotography (2000 editions two appendix IVA of Chinese Pharmacopoeia), the place measures trap respectively at the 220nm wavelength, calculates every burst size at different time by the ratio meter of the two trap.Every of this product should should be more than 20%～40%, 35%～60%, 50%～80% and 80% of labelled amount at 1 hour, 2 hours, 4 hours respectively mutually with 8 hours burst size.The results are shown in Table 1.
Table 1 three batch sample release results (% of unit)
| Lot number | Time (hour) | 1 | 2 | 3 | 4 | 5 | 6 | On average |
| 1 | 1 | 31.5 | 31.9 | 30.7 | 32.3 | 31.7 | 31.1 | 31.5 |
| 2 | 45.6 | 46.0 | 45.4 | 47.3 | 46.8 | 45.4 | 46.1 | |
| 4 | 65.9 | 61.6 | 64.5 | 65.9 | 66.5 | 65.4 | 65.1 | |
| 8 | 91.6 | 90.4 | 90.6 | 91.4 | 92.6 | 90.6 | 91.2 | |
| 2 | 1 | 30.5 | 32.5 | 30.7 | 33.2 | 29.4 | 31.5 | 31.3 |
| 2 | 45.2 | 46.8 | 44.6 | 47.3 | 44.8 | 44.2 | 45.5 | |
| 4 | 66.1 | 65.7 | 64.7 | 68.4 | 64.9 | 64.3 | 65.7 | |
| 8 | 91.0 | 91.8 | 90.6 | 90.8 | 93.3 | 90.4 | 91.3 | |
| 3 | 1 | 29.6 | 30.7 | 32.7 | 30.1 | 31.1 | 30.5 | 30.8 |
| 2 | 45.4 | 44.6 | 47.1 | 46.8 | 48.1 | 47.9 | 46.7 | |
| 4 | 65.7 | 64.7 | 66.1 | 68.8 | 66.7 | 67.2 | 66.4 | |
| 8 | 90.4 | 90.8 | 91.4 | 91.8 | 93.5 | 92.4 | 91.7 |
The drafting of release profiles
Get each 6 in the sample of embodiment 1 preparation, under above-mentioned release conditions, respectively at getting solution 5ml (and replenish immediately with volume water) in 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours respectively, through the 0.45um membrane filtration, discard filtrate just, precision measure subsequent filtrate 1ml with solvent dilution to 5ml as need testing solution; It is an amount of that precision takes by weighing the gastrodine reference substance in addition, and water is made the solution that contains 16ug among every 1ml approximately; Get above-mentioned two kinds of solution, according to spectrophotography (2005 editions two appendix IVA of Chinese Pharmacopoeia), the place measures trap respectively at the 220nm wavelength, calculates every burst size at different time by the ratio meter of the two trap.Obtain meansigma methods, draw release profiles,, see accompanying drawing 1 to investigate the release of this tablet with the release rate of different time.The results are shown in Table 2,3,4,5.
Release is calculated:
The release result (% of unit) of the 1st batch of six samples of table 2
| Time (hour) | 1 | 2 | 3 | 4 | 5 | 6 |
| 1 | 32.4 | 31.6 | 29.7 | 30.7 | 31.1 | 31.2 |
| 2 | 45.7 | 46.1 | 46.7 | 47.4 | 47.1 | 44.4 |
| 4 | 66.4 | 67.1 | 65.4 | 67.1 | 66.4 | 66.5 |
| 6 | 84.3 | 83.7 | 84.9 | 84.1 | 82.7 | 81.6 |
| 8 | 91.0 | 93.4 | 90.5 | 91.6 | 92.6 | 92.0 |
| 10 | 98.6 | 99.5 | 100.3 | 99.1 | 97.6 | 98.9 |
The release result (% of unit) of the 2nd batch of six samples of table 3
| Time (hour) | 1 | 2 | 3 | 4 | 5 | 6 |
| 1 | 30.1 | 31.4 | 31.8 | 33.4 | 32.8 | 32.0 |
| 2 | 46.5 | 48.2 | 46.3 | 47.6 | 48.8 | 47.8 |
| 4 | 64.2 | 66.5 | 65.4 | 65.8 | 64.6 | 63.8 |
| 6 | 85.3 | 87.0 | 86.6 | 86.2 | 84.1 | 84.5 |
| 8 | 93.7 | 94.3 | 92.0 | 93.0 | 95.5 | 92.2 |
| 10 | 99.5 | 98.6 | 101.6 | 100.5 | 99.3 | 101.1 |
The release result (% of unit) of the 3rd batch of six samples of table 4
| Time (hour) | 1 | 2 | 3 | 4 | 5 | 6 |
| 1 | 29.7 | 30.7 | 29.1 | 30.1 | 31.4 | 29.5 |
| 2 | 47.4 | 45.5 | 47.6 | 45.3 | 44.6 | 46.3 |
| 4 | 68.9 | 69.1 | 66.5 | 68.1 | 67.3 | 68.9 |
| 6 | 84.3 | 82.7 | 83.5 | 81.0 | 85.1 | 81.6 |
| 8 | 89.3 | 90.7 | 91.4 | 90.5 | 88.0 | 91.2 |
| 10 | 97.6 | 99.1 | 98.2 | 97.8 | 99.5 | 99.3 |
The release result of table 5 three batch samples (% of unit)
| Time (hour) | The 1st batch | The 2nd batch | The 3rd batch |
| 1 | 31.1 | 31.9 | 30.1 |
| 2 | 46.2 | 47.5 | 46.1 |
| 4 | 66.5 | 65.1 | 68.1 |
| 6 | 83.6 | 85.6 | 83.0 |
| 8 | 91.8 | 93.5 | 90.2 |
| 10 | 99.0 | 100.1 | 98.6 |
By release profiles as can be known, criticize in and batch between the release homogeneity good.Determine that with reference to slow release, controlled release and slowbreak preparation guideline (two appendix XIXD of Chinese Pharmacopoeia version in 2000) and three batch sample measured datas this product is respectively more than 20%～40%, 35%～60%, 50%～80% and 80% of labelled amount in the burst size of 1 hour, 2 hours, 4 hours and 8 hours.
Compare with the result who measures by gastrodine national standard WS1-XG-020-2001, preparation burst size disclosed by the invention was respectively more than 20%～40%, 35%～60%, 50%～80% and 80% of labelled amount in this product at 1 hour, 2 hours, 4 hours and 8 hours, thereby this product tool slow releasing function is described, can reduce the fluctuation of blood drug level, better the performance therapeutical effect has reached purpose of the present invention.
Preparation disclosed by the invention is through further stability study, its result shows that this preparation is stored at the drying at room temperature place, and its character, related substance, release, content etc. have no significant change, illustrate that it is stable at ambient temperature, can guarantee to transport, the quality of lay up period.
Claims (10)
1. a gastrodin slow release preparation contains gastrodine and pharmaceutically useful slow-release auxiliary material.
2. the preparation of claim 1, wherein pharmaceutically useful slow-release auxiliary material is a hydroxypropyl emthylcellulose, hydroxypropylmethyl cellulose phthalate, methylcellulose, ethyl cellulose, hydroxy methocel, hydroxyethyl-cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, acrylic resin, polymethyl methacrylate, crospolyvinylpyrrolidone, sodium alginate, calcium alginate, carbomer, polyvinyl alcohol, stearic acid, a kind of or its mixture in the chitosan, preferred hydroxypropyl methylcellulose HMPC, the more preferably mixture of HPMC-75RT15000 and HPMC-75RT4000.
3. claim 1 or 2 preparation also contain excipient, and excipient is one of microcrystalline Cellulose, lactose, sucrose, mannitol, dextran, sorbitol, starch, pregelatinized Starch, dextrin, calcium sulfate, calcium hydrogen phosphate or its mixture.
4. the preparation of claim 3, wherein gastrodine/pharmaceutically useful slow-release auxiliary material/excipient is 1: 0.5～3.0: 0.5～2.0 by weight.
5. the described preparation of above-mentioned arbitrary claim also contains binding agent, lubricant, and binding agent is a kind of or its mixture in polyvinylpyrrolidone alcoholic solution, starch slurry, syrup, water, the ethanol; Lubricant is a kind of or its mixture in stearic acid, magnesium stearate, calcium stearate, Pulvis Talci, silicon dioxide, micropowder silica gel, Polyethylene Glycol, Stepanol MG, the sodium lauryl sulphate.
6. the described preparation of claim 5, wherein gastrodine/lubricant is 1: 0.02～0.5 by weight.
7. the described preparation of claim 5, wherein volume ratio or weight ratio are 1: 0.001～0.005 to gastrodine/binding agent by weight.
8. the arbitrary described preparation of claim 6-7, wherein each components contents of unit formulation is:
Gastrodine 75mg
HPMC-75RT15000 54mg
HPMC-75RT4000 54mg
Microcrystalline Cellulose 84.3mg
The 75% alcoholic solution 0.2ml of 3%PVP
Magnesium stearate 2.7mg
9. aforesaid right requires arbitrary described preparation, can be tablet, capsule, granule, pill and coated slow release preparation, preferred coated tablet.
10. the described preparation of claim 9, wherein coating powder is a GS-N type coating powder in the coated tablet, the coating weightening finish is 2～5% by weight percentage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100482556A CN100363011C (en) | 2005-12-31 | 2005-12-31 | Gastrodin slow release preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100482556A CN100363011C (en) | 2005-12-31 | 2005-12-31 | Gastrodin slow release preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1823802A true CN1823802A (en) | 2006-08-30 |
| CN100363011C CN100363011C (en) | 2008-01-23 |
Family
ID=36934742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100482556A Expired - Fee Related CN100363011C (en) | 2005-12-31 | 2005-12-31 | Gastrodin slow release preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100363011C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188438A (en) * | 2010-03-05 | 2011-09-21 | 昆明制药集团股份有限公司 | Application of acetagastrodine in preparing medicines to prevent and treat vascular dementia (VD) and Alzheimer disease (AD) |
| CN102228449A (en) * | 2011-06-27 | 2011-11-02 | 昆明制药集团股份有限公司 | Gastrodin chronopharmaceutical medicine delivery preparation |
| CN103655585A (en) * | 2012-09-11 | 2014-03-26 | 上海星泰医药科技有限公司 | Gastrodin controlled release preparation and preparation method thereof |
| CN104971047A (en) * | 2015-06-16 | 2015-10-14 | 浙江中医药大学 | Nasal gastrodin pharmacia with biological adhesion characteristic, and preparation method thereof |
| CN109394698A (en) * | 2018-12-13 | 2019-03-01 | 怀化学院 | Gastrodin slow release suspension and preparation method thereof |
| CN112915066A (en) * | 2021-04-08 | 2021-06-08 | 贵州威门药业股份有限公司 | Glabrous sarcandra herb formula granules and preparation method thereof |
-
2005
- 2005-12-31 CN CNB2005100482556A patent/CN100363011C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188438A (en) * | 2010-03-05 | 2011-09-21 | 昆明制药集团股份有限公司 | Application of acetagastrodine in preparing medicines to prevent and treat vascular dementia (VD) and Alzheimer disease (AD) |
| CN102228449A (en) * | 2011-06-27 | 2011-11-02 | 昆明制药集团股份有限公司 | Gastrodin chronopharmaceutical medicine delivery preparation |
| CN102228449B (en) * | 2011-06-27 | 2013-04-10 | 昆明制药集团股份有限公司 | Gastrodin chronopharmaceutical medicine delivery preparation |
| CN103655585A (en) * | 2012-09-11 | 2014-03-26 | 上海星泰医药科技有限公司 | Gastrodin controlled release preparation and preparation method thereof |
| CN104971047A (en) * | 2015-06-16 | 2015-10-14 | 浙江中医药大学 | Nasal gastrodin pharmacia with biological adhesion characteristic, and preparation method thereof |
| CN104971047B (en) * | 2015-06-16 | 2017-09-26 | 浙江中医药大学 | Gastrodine nosal spherex with bio-adhesive characteristic and preparation method thereof |
| CN109394698A (en) * | 2018-12-13 | 2019-03-01 | 怀化学院 | Gastrodin slow release suspension and preparation method thereof |
| CN112915066A (en) * | 2021-04-08 | 2021-06-08 | 贵州威门药业股份有限公司 | Glabrous sarcandra herb formula granules and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100363011C (en) | 2008-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1823802A (en) | Gastrodin slow release preparation | |
| CN1957928A (en) | Controlled release preparation of clinical treating medication, and fabricating method | |
| CN103479592B (en) | Metformin hydrochloride sustained release tablets and preparation method thereof | |
| CN1698741A (en) | Gingko leaf slow-releasing tablet and preparation process thereof | |
| CN1799543A (en) | Telmisartan dispersible tablet and its preparation method | |
| CN1095665C (en) | Modified-release metronidazole compositions and methods for making and using same | |
| CN101032462A (en) | Mexiletine Hydrochloride slow release reagent and preparing method thereof | |
| CN1254246C (en) | Oral disintegration tablet of silaenafil and its pharmaceutically receptible salt and its preparing method | |
| CN1965817A (en) | Sustained release tablet of glibenclamide and preparation process thereof | |
| CN1732953A (en) | Dispersible tablet for treating hypertension | |
| CN1919185A (en) | Compound ammonium glycyrrhizinato S dispersed tablet and its preparing process | |
| CN1443535A (en) | Tegasevod maleate oral preparation and its preparation process-for curing intestinal irritability syndrome | |
| CN1264520C (en) | Enteric-coated azithromycin preparation and its preparing process | |
| CN1887277A (en) | Dispersant tablet containing hypolipidemic component and its prepn process | |
| CN1634087A (en) | Sustained release formulation of glucosamine salt, its preparation and usage | |
| CN1853634A (en) | Composition comprising itraconazole for oral administration | |
| CN100336511C (en) | Release-controlled oral Roxithromycin formulation | |
| CN103385862B (en) | A kind of metoprolol tartrate extended release tablets and preparation method thereof | |
| CN1175811C (en) | Slow-releasing Anixitan tablet | |
| CN1197571C (en) | Metronidazole, Clotrimazole and Chlorhexidime Acetate preparation and its preparing method | |
| CN1895250A (en) | Gliquilone slow-releasing preparation | |
| CN1600313A (en) | Cefetamet pivoxil hydrochloride dispersion dispersion tablets and preparation method | |
| CN100340239C (en) | Andrographolide dispersing tablets | |
| CN1868472A (en) | Tablets of Lizakuputan benzoate | |
| CN1164265C (en) | Release controlled tuoteluoding tartrate and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080123 Termination date: 20111231 |